MIRA INFORM REPORT

 

 

Report Date :           

06.06.2011

 

IDENTIFICATION DETAILS

 

Name :

VALOR PHARMACEUTICALS

 

 

Registered Office :

Plot No. 124-A, Kahuta Triangle, Islamabad

 

 

Country :

Pakistan

 

 

Year of Establishment :

2000

 

 

Legal Form :

Partnership Concern

 

 

Line of Business :

Manufacture & Marketing of Pharmaceutical Products

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Status :

Moderate

Payment Behaviour :

No Complaints

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – March 31st, 2011

 

Country Name

Previous Rating

                   (31.12.2010)                  

Current Rating

(31.03.2011)

Pakistan

b2

b2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 Bottom of Form

 

Business Name

 

VALOR PHARMACEUTICALS

 

 

Full Address       

 

Registered Address & Factory

Plot No. 124-A, Kahuta Triangle, Islamabad, Pakistan

                       

Tel #

92 (51) 4491616, 4491632

Fax #

92 (51) 4491632

 

           

Short Description Of Business

 

a.

Nature of Business        

Manufacture & Marketing of Pharmaceutical Products

b.

Year Established

2000

c.

National Tax #

1408203

 

 

Branches

                       

Address

Office # 20, Park View Colony, Opposite Ayub National Park, Jehlum Road Rawalpindi, Pakistan

Tel #

92 (51) 5488288, 5488299

Fax #

92 (51) 5488499, 5487733

 

 

Legal Status

 

Subject Company was established as a Partnership business in 2000

 

 

Details of Managing Partner / Partners

 

Names

Nationality

Address

Occupation

Designation

Mr. Ishtiaq Ahmed

 

 

 

Mr. Sohail Ahmed

Pakistani

 

 

 

Pakistani

Plot No. 124-A, Kahuta Triangle, Islamabad

 

Plot No. 124-A, Kahuta Triangle, Islamabad

Business

 

 

 

Business

Managing Partner

 

 

Partner

 

 

 

 

Associates                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

 

A.         Subsidiary

 

                        None                                             

           

B.         Associated Companies

 

(1) Al Hameed Agencies, Pakistan         

 

 

Products

 

(1) Subject Company is engaged in manufacture & marketing of Pharmaceutical Products by its brand names of ACIDRAN, ACNE LENE, AMCINIDE, AMPROX, BENCLAMIDE, BETAGENT, BETANATE, BETASALY, BETAVAL, CETOPRESS, CORNIT, CORTIDERM, CORTIVAL, DENSER, DISCLOT, FERUS, FLAMOFF, GAXIN, GERMINIL, HEMOLYTE, ISOCON, K-TAB, KETOCON, LECIN, LENOMIDE, LICE-O MITE, LYOFAM, MAPRID, MENDAZOLE, METFOR, MEZAPINE, MYCON, MYCON-H, NAMIC, NIMSULID, NOACIN, NORMET, OMEPRAVAL, ORPHENA, PANTOZOL, PEBACT, PHAROX, PHENIR, POLYMYX, PRUFO, ROXYZIN, SEPTINIL, SIGNA, SPAROCIN, TIFCIN, TRIMELASIN, TRITON, UDIC, UFENAC, URBOFEN, VALIDOPA, VALOMAG, VALOPALAC, VALOPRIL, VALOSAL, VAMOL, VANDAN, VASIMET, VASPRIN, ZORAXIN.

 

(2)   It purchases raw material against L/C, D/A, D/P basis

 

(3)   It sells against Cash / Credit Terms to its local customers.

 

(4) Its’ major customers are Distributors, Traders, Pharmacies & Hospitals located at major cities of Pakistan.

 

(5) Subject operates from caption leased factory premises situated at industrial area.

 

(6)  Subject employs about 82 persons in its set up.

 

 

Annual Sales Volume

 

Year

In Pak Rupees

2009

100,000,000/- (Estimated)

 

 

 

Capacity & Production

           

The capacity and production of the company’s plant is indeterminable as it is multi- product and involves various processes of manufacture.

 

 

Authorized Distributors

 

Mainly exist at major cities of Pakistan                  

 

 

Bankers

 

·         Habib Bank Limited, Pakistan.

·         The Bank of Punjab, Pakistan.

·         Standard Chartered Bank, Pakistan.

·         Bank Alfalah Limited, Pakistan.

·         MCB Bank Limited, Pakistan.

 

 

Foreign Exchange Rates

 

Currency

 

Unit

Pakistani Rupee

US Dollar

1

           Rs. 86.00

UK Pound

1

           Rs. 140.71

Euro

1

           Rs. 125.31

 

 

Memberships

 

·         Rawalpindi Chamber of Commerce & Industry.

 

 

Comments

 

Subject Company was established in 2000 and is engaged in manufacture & marketing of Pharmaceutical Products. Trade relations are reported as fair. Subject can be considered for normal business dealings at usual trade terms and conditions.

 

 

 

 

 

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.44.85

UK Pound

1

Rs.73.29

Euro

1

Rs.64.89

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.